About the Event
In this installment of Psychiatry and Behavioral Sciences Grand Rounds, Sagar V. Parikh, M.D., FRCPC, presents “Real-World Bipolar Disorder: A Case-Based Audience-Response Treatment Journey.” Parikh is the John F. Greden Professor of Depression and Clinical Neuroscience and a professor in the departments of Psychiatry and Health Management and Policy at Michigan Medicine.
For more information about the event, email Jennifer Braham.
Upon request, Dell Medical School will provide interpretation services at this event. Please notify Jennifer by Dec. 15, 2023, if interpretation is needed.
Learning Objectives
By the end of this presentation, the audience participant should be able to:
- Clarify principles for creation of CANMAT/ISBD bipolar guidelines.
- Identify strategies for selecting best treatments for each phase of bipolar disorder.
- Analyze these strategies collaboratively by applying treatments to a case study.
Target Audience
- Primary: Psychiatrists, social workers, psychologists, nurses and other mental health professionals
- Secondary: Other health care professionals
Attributes/Competencies
This activity has been designed to promote some of the following desired physician attributes and competencies:
- ACGME: Patient Care; Medical Knowledge; Practice-Based Learning and Improvement; Interpersonal and Communication Skills; Professionalism; Systems-Based Practice.
- IOM: Provide patient-centered; Work in interdisciplinary teams; Employ evidenced-based practice; Apply quality improvement; Utilize informatics
- IECC: Interprofessional Teamwork & Team-based Practice; Interprofessional Communication; Values & Ethics for Interprofessional Practice
Speaker Disclosure
Sagar V. Parikh, M.D., FRCPC, speaker for this educational activity, received grants/research support from Janssen, Sage, Aifred, COMPASS and Merck through University of Michigan contracts. He is a consultant for Assurex/Myriad, Sage, Mensante, Neonmind and Aifred. He received an honorarium from Janssen and Boehringer Ingelheim for attending an advisory board research meeting and an honorarium from Otsuka for presenting. Parikh has been granted shares of Mensante.
Planner Disclosure
Mark H. Townsend, M.D., M.S.; Carol L. Alter, M.D.; Lloyd S. Berg, Ph.D., ABPP; Octavio N. Martinez Jr., M.D., MPH; Barbara Springer; and Jennifer Braham, M.S., planners for this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.
Jeffrey Newport, M.D., M.S., MDiv, planner for this educational activity, received grants/research support from Navitor Pharmaceuticals and Sage Therapeutics, and he is a consultant for Sage Therapeutics. He received an honorarium for serving on the advisory board of Sage Therapeutics, Merck and Janssen.
Charles B. Nemeroff, M.D., Ph.D., planner for this educational activity, is a consultant for ANeuroTech (division of Anima BV), Signant Health, Janssen Research & Development LLC, BioXcel Therapeutics, Silo Pharma, Engrail Therapeutics, Clexio Bioscience LTD, EcoR1 Capital LLC, EmbarkNeuro (formerly AncoraBio), Galen Mental Health LLC, Goodcap Pharmaceuticals Inc., ITI Inc., LUCY Scientific Discovery, Relmada Therapeutics Inc., Sage Therapeutics, Senseye Inc., and Precisement Health. He is a stock shareholder (directly purchased) of Xhale, Seattle Genetics, Antares, BI Gen Holdings Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness, Precisement Health, and Relmada Therapeutics Inc. Nemeroff is on the scientific advisory boards for ANeuroTech (division of Anima BV), Signant Health, Laureate Institute for Brain Research (LIBR) Inc., Galen Mental Health, LLC, Heading Health, LLC, Pasithea Therapeutics Corp, Sage Therapeutics, Inc and Senseye, Inc. He holds patents for the following: Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).
The CME Advisory Committee, reviewers of this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.
All the relevant financial relationships listed for these individuals have been mitigated.
Accreditation Statement
The University of Texas at Austin Dell Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas at Austin Dell Medical School designates this live course for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.